225 related articles for article (PubMed ID: 25481269)
21. 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma.
Aboelnaga MM; Abdullah N; El Shaer M
Endocr Metab Immune Disord Drug Targets; 2017; 17(3):219-225. PubMed ID: 28595559
[TBL] [Abstract][Full Text] [Related]
22. Update on prolactinomas. Part 2: Treatment and management strategies.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
[TBL] [Abstract][Full Text] [Related]
23. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.
Fleseriu M; Lee M; Pineyro MM; Skugor M; Reddy SK; Siraj ES; Hamrahian AH
J Neurooncol; 2006 Aug; 79(1):41-3. PubMed ID: 16598425
[TBL] [Abstract][Full Text] [Related]
24. Invasive Giant Prolactinoma.
Alkhaibary A; Alharbi A; Khairy S
World Neurosurg; 2024 Jan; 181():21-22. PubMed ID: 37827431
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of curative effect of surgical therapy for male prolactinoma].
Chen MT; Song YJ; Lian W; Xing B; Yao Y; Feng M; Wang RZ
Zhonghua Yi Xue Za Zhi; 2016 May; 96(19):1477-80. PubMed ID: 27266490
[TBL] [Abstract][Full Text] [Related]
26. Mass screening for hyperprolactinemia and prolactinoma in men.
Miyake A; Ikegami M; Chen CF; Arita N; Aono T; Tanizawa O; Yoshikawa T
J Endocrinol Invest; 1988 May; 11(5):383-4. PubMed ID: 3183301
[TBL] [Abstract][Full Text] [Related]
27. Computed tomography of the brain in patients with serum prolactin levels over 200 ng/ml.
Chang YC; Liu HM; Huang KM; Wang TC; Hsu JC
J Formos Med Assoc; 1991 Feb; 90(2):146-52. PubMed ID: 1678408
[TBL] [Abstract][Full Text] [Related]
28. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
29. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.
Greenman Y; Tordjman K; Stern N
Clin Endocrinol (Oxf); 1998 May; 48(5):547-53. PubMed ID: 9666865
[TBL] [Abstract][Full Text] [Related]
30. The effect of external pituitary irradiation on elevated serum prolactin levels in patients with pituitary macroadenomas.
Littley MD; Shalet SM; Reid H; Beardwell CG; Sutton ML
Q J Med; 1991 Dec; 81(296):985-98. PubMed ID: 1808643
[TBL] [Abstract][Full Text] [Related]
31. High prolactin level.
Piketty ML; Nataf F; Dilouya A; Roux FX
J Neurosurg; 2000 Feb; 92(2):368-9. PubMed ID: 10659034
[No Abstract] [Full Text] [Related]
32. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
33. Role of Ki-67 in acromegalic patients with hyperprolactinemia: retrospective analysis in 61 Chinese Patients.
Huan C; Cui G; Lu C; Qu X; Han T
Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):719-23. PubMed ID: 25796164
[TBL] [Abstract][Full Text] [Related]
34. [Hyperprolactinemia in patients with non-functioning adenoma: analysis of 85 patients treated by transsphenoidal operation].
Saitoh Y; Mori S; Arita N; Hayakawa T; Mogami H; Oku Y; Onishi T; Uozumi T
No Shinkei Geka; 1987 Nov; 15(11):1175-9. PubMed ID: 3437926
[TBL] [Abstract][Full Text] [Related]
35. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance.
Elenkova A; Genov N; Abadzhieva Z; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):201-5. PubMed ID: 23595795
[TBL] [Abstract][Full Text] [Related]
36. Speed of response to dopaminergic agents in prolactinomas.
Hage C; Salvatori R
Endocrine; 2022 Mar; 75(3):883-888. PubMed ID: 34846682
[TBL] [Abstract][Full Text] [Related]
37. Serum Prolactin Level to Tumor Size Ratio as a Potential Parameter for Preoperative Differentiation of Prolactinomas from Hyperprolactinemia-Causing Non-functional Pituitary Adenomas.
Kim JH; Hur KY; Hong SD; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
World Neurosurg; 2022 Mar; 159():e488-e496. PubMed ID: 34958988
[TBL] [Abstract][Full Text] [Related]
38. MRI--diagnostic and follow-up tool for microprolactinomas.
Seidl Z; Obenberger J; Marek J; Hána V; Vanĕcková M
Funct Neurol; 2000; 15(1):47-51. PubMed ID: 10842760
[TBL] [Abstract][Full Text] [Related]
39. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?
Perić B; Kruljac I; Šundalić S; Pećina HI; Jović A; Štefanović M; Butorac D; Vrkljan M
Endocr Res; 2016 Aug; 41(3):200-6. PubMed ID: 26864960
[TBL] [Abstract][Full Text] [Related]
40. Serum prolactin bioactivity and immunoactivity in hyperprolactinaemic states.
Smith CR; Butler J; Hashim I; Norman MR
Ann Clin Biochem; 1990 Jan; 27 ( Pt 1)():3-8. PubMed ID: 2310154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
